SPNE - SPNE STOCK NEWS

SeaSpine Holdings Corporation (NASDAQ: SPNE) has announced the full commercial launch of its innovative 3D-printed WaveForm TO Interbody System. This product is designed to enhance surgical procedures for spinal disorders by offering versatile options for PLIF and TLIF. The company anticipates addressing a $500 million market opportunity through this launch. Key features include a robust design for improved fusion and compatibility with existing systems. The WaveForm technology aims to optimize key surgical metrics such as subsidence resistance and radiographic visualization.

SeaSpine Holdings Corporation (NASDAQ: SPNE) reported a 21% year-over-year revenue increase to $50.7 million for Q1 2022. U.S. revenue reached $45.5 million, driven by spinal implants with a 31% growth to $24.2 million. Despite increased revenues, the company faced a net loss of $16.6 million, impacted by higher operating expenses and technology amortization from the acquisition of 7D Surgical. SeaSpine raised its full-year 2022 revenue guidance to $231-$235 million, anticipating strong U.S. spinal implant growth exceeding 20%.

SeaSpine Holdings Corporation (NASDAQ: SPNE) announced leadership changes, appointing John Bostjancic as Chief Operating and Financial Officer, having previously served as CFO since 2015. He will focus on operational excellence across product development and supply chain. The company also welcomed Hollis Winkler as Senior Vice President, Human Resources, responsible for talent management and employee engagement. CEO Keith Valentine expressed confidence in the team’s ability to drive growth and operational efficiencies within the spine market, aiming for revenue growth above market standards.

SeaSpine Holdings Corporation (NASDAQ: SPNE) has launched OsteoTorrent and OsteoTorrent C, innovative dry Accell DBM Putties aimed at enhancing osteoinductive potential and shelf-life. These products allow for reconstitution with various fluids, improving usability for surgeons. The launch positions SeaSpine as the #2 DBM supplier in the U.S. and showcases the company’s commitment to R&D. The inaugural surgeries were performed by Dr. Gerard Girasole, further establishing the new products' market presence.

SeaSpine Holdings Corporation (NASDAQ: SPNE) has announced the commercial launch of the Explorer TO Expandable Interbody System, designed for spinal surgery. This system features two types of implants that expand in height and lordosis, enhancing surgical efficiency. With an addressed market potential exceeding $450 million in the U.S., this product positions SeaSpine competitively in the expandable interbody market. The company aims to develop more systems in the future, addressing various surgical techniques and approaches.

SeaSpine Holdings Corporation (NASDAQ: SPNE) announced it will release its first quarter financial results on May 3, 2022, after market close. Management will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET to discuss the results. Interested parties can listen by calling (877) 418-4766 for domestic or (614) 385-1253 for international callers, using Conference ID: 9979866. SeaSpine specializes in surgical solutions for spinal disorders, featuring innovative technologies like FLASH™ Navigation and a robust portfolio of spinal implants.

SeaSpine Holdings Corporation (NASDAQ: SPNE) announced the full commercial launch of the Reef TA Interbody System on April 11, 2022. This innovative system is designed for optimal spinal alignment, featuring various footprint options to meet surgeons' specific anatomical needs. The Reef TA uses NanoMetalene® surface technology to enhance bone integration while maintaining PEEK's biocompatibility. Surgeons report positive feedback on its user-friendly design and effective results. SeaSpine aims to serve patients with spinal disorders through advanced surgical solutions and is actively marketing its products globally.

SeaSpine Holdings Corporation (NASDAQ: SPNE) announced the successful implantation of its 50,000th NanoMetalene® interbody device, highlighting the rapid adoption of this proprietary surface technology within just over two years. The NanoMetalene technology integrates a titanium layer with PEEK implants, ensuring biocompatibility and excellent radiographic visibility. This milestone underscores SeaSpine’s commitment to enhancing surgical outcomes and innovation with future-focused designs like Reef Topography™ and WaveForm 3D. The company aims to continue leveraging scientific advancements for improved spinal fusion procedures.

SeaSpine Holdings Corporation (NASDAQ: SPNE) announced its participation in the Canaccord Musculoskeletal Conference on March 22, 2022, at 2:30 pm ET. A live and archived webcast will be accessible through the SeaSpine website.

SeaSpine specializes in surgical solutions for spinal disorders, providing a portfolio of orthobiologics and spinal implants, as well as surgical navigation systems for neurosurgeons and orthopedic spine surgeons.